In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar; ...
AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's ...
AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...
Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...
Shares of AbbVie (ABBV) rose after the biotech firm exceeded sales estimates and gave a positive outlook for revenue from its Skyrizi and Rinvoq treatments. Tesla (TSLA) shares climbed on a report ...
AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat ...
Jamie Kelter Davis / Bloomberg via Getty Images AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two ...
AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.
AbbVie (ABBV) came out with quarterly earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $2.79 per share a year ago. These figures ...
NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier. On a ...